BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019)
In this 800-pages report, a must-have read one, you will find included:
More than 230 closely scrutinized companies More than 600 products identified including more than 200 products at the clinical stage A Product Breakdown by Development Phase More than 300 VC or investors mentioned More than 250 pathologies referred.
A Detailed Overview of Companies Involved in:
AAV-based Gene Therapy LV-based Gene Therapy RNA-based Derived Drugs (RNAi, mRNA Therapeutics…) Gene Editing Therapy CDMO (Contract, Development and Manufacturing Organisation) Miscellaneous (Including Hubs and Non Viral Gene Transfer)*
Each Technical Datasheet includes for Every Company:
– General Informations (location, website, FTE, management with e-mail contacts)
– Core Business in Gene Therapy
– Financial Data (stock informations, market cap, financial highlights, recent fundings….)
– Pipeline (discovery, pre-clinical, phase I / II / III, marketed products)
– Orphan Drug Designations
– Clinical Trials – Latest Developments in Gene Therapy
– Latest Publications
* CAR-T strategies will be dealt separately in the updated edition of our briefing on CAR-T clinical trials. The 2019 edition will be published next November.
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019)
In this 800-pages report, a must-have read one, you will find included:
More than 230 closely scrutinized companies More than 600 products identified including more than 200 products at the clinical stage A Product Breakdown by Development Phase More than 300 VC or investors mentioned More than 250 pathologies referred.
A Detailed Overview of Companies Involved in:
AAV-based Gene Therapy LV-based Gene Therapy RNA-based Derived Drugs (RNAi, mRNA Therapeutics…) Gene Editing Therapy CDMO (Contract, Development and Manufacturing Organisation) Miscellaneous (Including Hubs and Non Viral Gene Transfer)*
Each Technical Datasheet includes for Every Company:
– General Informations (location, website, FTE, management with e-mail contacts)
– Core Business in Gene Therapy
– Financial Data (stock informations, market cap, financial highlights, recent fundings….)
– Pipeline (discovery, pre-clinical, phase I / II / III, marketed products)
– Orphan Drug Designations
– Clinical Trials – Latest Developments in Gene Therapy
– Latest Publications
* CAR-T strategies will be dealt separately in the updated edition of our briefing on CAR-T clinical trials. The 2019 edition will be published next November.
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019)
In this 800-pages report, a must-have read one, you will find included:
More than 230 closely scrutinized companies More than 600 products identified including more than 200 products at the clinical stage A Product Breakdown by Development Phase More than 300 VC or investors mentioned More than 250 pathologies referred.
A Detailed Overview of Companies Involved in:
AAV-based Gene Therapy LV-based Gene Therapy RNA-based Derived Drugs (RNAi, mRNA Therapeutics…) Gene Editing Therapy CDMO (Contract, Development and Manufacturing Organisation) Miscellaneous (Including Hubs and Non Viral Gene Transfer)*
Each Technical Datasheet includes for Every Company:
– General Informations (location, website, FTE, management with e-mail contacts)
– Core Business in Gene Therapy
– Financial Data (stock informations, market cap, financial highlights, recent fundings….)
– Pipeline (discovery, pre-clinical, phase I / II / III, marketed products)
– Orphan Drug Designations
– Clinical Trials – Latest Developments in Gene Therapy
– Latest Publications
* CAR-T strategies will be dealt separately in the updated edition of our briefing on CAR-T clinical trials. The 2019 edition will be published next November.
COMMENTS ARE OFF THIS POST